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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not “Is
Apremilast 30 mg effective in lowering DLQI scores in patients with plaque psoriasis in 16
weeks of therapy?”
Study Design: Review of three randomized, blind, placebo-controlled clinical trials published
between the years 2013 and 2016.
Data Sources: All studies were published in peer-reviewed journals that were located using
PubMed database searches.
Outcome Measured: The DLQI is a 10-item questionnaire that assesses the impact of skin
disease on health-related quality of life (HRQOL) over the previous week. Scores for each item
range from 0 (not at all affected) to 3 (very much affected); total scores range from 0 to 30 and
those >10 represent a very large impact on HRQOL. Patients answered questions regarding their
physical discomfort and limitations in activities of daily living to psychosocial problems and
emotional distress caused by the condition.
Results: All studies showed a statistical significance when comparing Apremilast 30mg BID to a
placebo therapy. DLQI scores were decreased by 6.7 points in the study performed by Paul et al.,
8.3 points with Reich et al. data, and lastly 4.4 points with the Strand et al. study. (P- values for
all studies <0.05)
Conclusion: According to this EBM review Apremilast 30mg is effective in lowering DLQI
scores in patients with plaque psoriasis in 16 weeks of therapy. Some studies showed more
significant decreases in DLQI scores but overall a patient would experience a lower impact of
skin disease on health-related quality of life.
Key Words: Apremilast, Plaque Psoriasis.
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INTRODUCTION
Plaque psoriasis is a common chronic inflammatory skin disease that is characterized by
well-demarcated, erythematous plaques with an overlying silver scale. Pruritis is the main
symptom patients physically experience and varies from mild to severe.1 Often the disease is
asymptomatic, but other symptoms may include skin pain or Auspitz sign, which is pin-point
bleeding when there is minor abrasion to a plaque.1 Plaque psoriasis can affect patients in
varying degrees of severity; some patients having minimal visible skin lesions while others
experience a greater percentage of their body surface area being covered. Smaller areas of
plaques often will coalesce into larger plaques causing increased physical and psychosocial
discomfort.1 Typically the scalp, lower back, trunk, and extremities are involved but the extensor
surfaces of joints such as the elbows and knees have an increased predilection.2 Psoriasis may
not produce physical discomfort for all patients but it is associated with potentially antagonistic
effects on mental health.2 Patients are at increased risk for depression, anxiety, and suicidality
when compared with the general population.3 Due to these factors many patients elect to begin
treatment to increase their overall quality of life and social interactions.
Although earlier concepts of the pathogenesis of psoriasis were more focused on
keratinocyte hyperproliferation, dysregulation of the immune system is now recognized as the
main cause of the disease.1 The interactions between dendritic cells, T cells, keratinocytes,
neutrophils, and the cytokines released from immune cells likely contribute to the initiation of
the cutaneous skin inflammation that is characteristic of psoriasis.4 There is also a genetic factor
to consider, as approximately 40% of patients with psoriasis have a family history of the disease
in a first-degree relative.5 Other factors that play a role in the development of psoriasis include
tobacco and alcohol use, certain medications, infections, and stress.6
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Psoriasis is estimated to affect more than 8 million Americans and is one of the most
common dermatologic and autoimmune conditions treated in the world.2 There are
approximately 150,000 cases of psoriasis that are diagnosed annually, which contributes to 3
million visits to healthcare facilities for treatments.7 With treatments often requiring the use of
biologic agents healthcare costs can be overwhelming to a patient. Biologics as a mainstay for
treatment can have a mean annual cost of $53,183.50 for a patient paying out of pocket.8 The
total burden of psoriasis was recently estimated as $35.2 billion in the United States.9
There is currently no cure for psoriasis as it is considered a chronic condition. Therapies
are targeted at reducing the appearance and size of lesions as well as any associated discomfort.
Topical therapies are recommended in mild disease states and emphasis on keeping the skin
moisturized is stressed.2 These therapies include emollients, corticosteroids, Vitamin D analogs,
calcitriol, tar shampoos, taxarotene, and calcineurin inhibitors.6 When the disease is affecting a
larger body surface area ultraviolet light therapy may be recommended but can cause a patient to
be more at risk to develop a skin malignancy.6 In severe cases systemic agents such as
methotrexate, etanercept, infliximab, and adalimumab may be indicated.6
These agents mentioned can help control the extensiveness of psoriasis but can be
associated with negative side effects, increased medical costs, delayed response to treatment, and
poor patient satisfaction.10 It is important to have a drug that is designed to directly target the
formation of psoriasis and also achieve a higher level of patient satisfaction. Apremilast, a
phosphodiesterase 4 inhibitor, is an oral agent for the treatment of moderate to severe plaque
psoriasis.10 Phosphodiesterase 4 inhibition reduces production of multiple cytokines involved in
the pathogenesis of psoriasis.11 This paper assesses the efficacy of Apremilast in improving a
patient’s quality of life in a 16 week period.
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OBJECTIVE
The objective of this selective evidence based medicine (EBM) review is to determine
whether or not “Is Apremilast 30 mg effective in lowering DLQI scores in patients with plaque
psoriasis in 16 weeks of therapy?”
METHODS
In order to be considered and included, the population studied had to be patients 18 years
of age or older clinically diagnosed with chronic plaque psoriasis for 6 months or longer. The
study had to be a randomized controlled trial that included a treatment group taking Apremilast
30mg orally twice day (BID) and the control group receiving a placebo. Outcomes were
measured using Dermatology Life Quality Index (DLQI) self-report questionnaire scores and
their mean change from baseline at 16 weeks of treatment.
To find appropriate articles, keywords that were used included: “Apremilast”; “Plaque
Psoriasis”. Articles had to be in the English language and published in peer-reviewed journals.
The author used the listed keywords to search online PubMed databases that addressed the
objective of this review and used a patient centered outcome to measure the overall effect on a
patient’s quality of life. For an article to be considered it had to be a randomized, blinded,
placebo-controlled trial using Apremilast as a treatment option. These articles had to be
published within the last 10 years to ensure all data was up to date. If an article included patients
under the age of 18 it would be rejected and excluded from the data. The specific demographics
and characteristics for each individual study can be found in Table 1.
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TABLE 1: DEMOGRAPHICS & CHARACTERISTICS OF INCLUDED STUDIES
Study
Paul et
al.11
(2015)

Type

#
Age
Inclusion
Pts. (years) criteria
RCT,
411 45.3
Adults ³18
double
±13.1 years of age
blinded,
were eligible if
placebo
diagnosed with
controlled
chronic plaque
psoriasis for ³
12 months.
Patients had
moderate-tosevere plaque
psoriasis,
defined as
Psoriasis Area
and Severity
Index (PASI)
score ³ 12.

Reich et RCT,
al.12
double(2017)
blind,
placebocontrolled
study

167

46.0
±13.6

Strand
et al.10

176

44.1 ± Adults ³18
14.7
years of age
with stable,
chronic,
moderate to
severe plaque
psoriasis (PASI
³12 for ³ 6
months) who
were
candidates for
therapy.

(2013)

RCT,
blinded,
placebocontrolled

Adults aged
≥18 years were
eligible if they
had chronic
plaque
psoriasis for
≥12 months
(PASI score
≥12).
No prior
exposure to a
biologic
therapy for
psoriasis or
psoriatic
arthritis.

Exclusion Criteria

W/D

Interventions

Clinically significant
cardiac, endocrinological,
pulmonary, neurological,
psychiatric, hepatic, renal,
hematological or
immunological disease;
other major uncontrolled
disease.
Prolonged sun or
ultraviolet exposure.
Biologic therapy within
12-24 weeks, conventional
systemic treatments within
4 weeks, topical treatments
for psoriasis within 2
weeks.

60

Regimen of
Apremilast
30mg orally
BID

Patients with prior failure
of >3 systemic agents for
treatment of psoriasis
History of known
demyelinating diseases
such as multiple sclerosis
or optic neuritis or history
of or concurrent congestive
heart failure, including
medically controlled,
asymptomatic congestive
heart failure; other
clinically significant or
major uncontrolled disease

15

Regimen of
Apremilast
30mg orally
BID

Concomitant phototherapy LOCF
and use of systemic
used
biologic agents, use of
topical agents except for
Eucerin cream; low
potency corticosteroids for
facial, axillary, and groin
lesions; and coal tar
shampoo or salicylic acid
preparations for scalp
lesions.

Regimen of
Apremilast
30mg orally
BID
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OUTCOMES MEASURED
The outcomes were measured using the Dermatology Life Quality Index (DLQI) which is
a 10-item questionnaire that assesses the impact of skin disease on health-related quality of life
(HRQOL) over the previous week. Questions range from physical discomfort and limitations in
activities of daily living to psychosocial problems and emotional distress experienced by the
patient. Scores for each item range from 0 (not at all affected) to 3 (very much affected); total
scores range from 0 to 30 and those >10 represent a very large impact on HRQOL. 10,11,12 The
mean change from the baseline score at the start of therapy was collected at week 16 as well as
other time intervals.
RESULTS
The three studies selected compared the effectiveness of Apremilast 30mg twice a day to
a placebo when treating adults with chronic plaque psoriasis. All studies used the DLQI
questionnaire to evaluate if the treatment given caused an overall improvement and mean change
from baseline over a set of timed intervals (Table 2). Each study also included a P-value to show
the statistical significance of Apremilast versus a placebo (Table 3).
TABLE 2. DLQI MEAN CHANGE FROM BASELINE IN 16 WEEKS
DLQI Mean Change
from Baseline ± SD
with Apremilast 30mg
DLQI Mean Change
from Baseline ± SD
with Placebo

Study 1

Study 2

Study 3

-6.7

-8.3±7.7

-4.4 ±5.1

-2.8

-3.8±5.6

−1.9 ± 5.2

TABLE 3. STATISTICAL SIGNIFICANCE OF INTERVENTION VS. PLACEBO
P- Value

Study 1

Study 2

Study 3

P<0.001

P<0.0001

P£0.005

*Statistical significance was considered to be a p-value <0.05
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The first study by Paul et al., was a phase III, randomized, double-blind, placebocontrolled study that monitored the efficacy and safety of Apremilast 30mg twice a day over 52
weeks compared to a placebo. The study included three time periods, week 16, week 32, and
week 52, where patient data was collected. It specifically excluded patients who had used
biologics within 12-24 weeks, conventional systemic treatments within 4 weeks, topical
treatments for psoriasis within 2 weeks, and anyone with prolonged sun or ultraviolet exposure.
Such factors could cause a patient to experience a decrease in DLQI scores that are unrelated to
Apremilast treatment. Additional exclusion and inclusion criteria can be seen in Table 1.
Apremilast showed significant improvement at week 16 of the study with 70.8% of the
population that had a DLQI score >5 decreasing their DLQI score by 5 or more points (Table 4).
The mean change from baseline reported by the study showed overall a 6.7 point decrease in
DLQI scores in patients treated with Apremilast 30mg twice a day (Table 2). Within the 16-week
period 60 of 411 patients discontinued treatment due to multiple factors (Table 5). Missing data
was handled with last-observation-carried-forward (LOCF) methodology.
TABLE 4. DLQI RESPONSE (DECREASE OF ³ 5 POINTS) IN 16 WEEKS
Placebo (%)

Apremilast 30 mg (%)

P-Value

Study 1

42.9

70.8

<0.001

Study 2

41.7

65.1

0.0032

TABLE 5. PATIENTS COMPLIANCE WITH INTERVENTION IN STUDY 1
Discontinued
due to:

Adverse
event

Lack of
efficacy

Withdrawn
consent

Protocol
violation

NonOther
Compliant

Total

7

Lost to
followup
6

Placebo
Group
(n=137)
Apremilast
30mg BID
(N=274)

8

2

1

0

1

25

12

3

9

6

2

1

2

35
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The second study by Reich et al., was a phase IIIb, randomized, double blind, placebocontrolled study that monitored the efficacy and safety of Apremilast 30mg twice a day and
Etanercept 50mg once daily subcutaneous injection compared to a placebo. The trial included a
placebo-controlled phase through 16 weeks with the 3 separate test groups as well as an
Apremilast extension phase through 52 weeks. It specifically included patients who had
previously had inadequate response, intolerance or contraindication to ≥1 conventional systemic
agents for treatment of psoriasis, were candidates for phototherapy or systemic therapy, and had
no prior exposure to a biologic therapy for psoriasis or psoriatic arthritis. Additional criteria can
be seen in Table 1. Apremilast again showed significant improvement at week 16 of the study
with 65.1% of the population that had a DLQI score >5 decreasing their DLQI score by 5 or
more points (Table 4). The mean change from baseline reported by the study showed overall a
8.3 point decrease in DLQI scores in patients treated with Apremilast 30mg twice a day (Table
2). Within the 16-week period 15 of 167 patients discontinued treatment due to multiple factors
(Table 6). Last observation carried forward (LOCF) methodology was used to impute missing
efficacy measurements.
TABLE 6. PATIENTS COMPLIANCE WITH INTERVENTION IN STUDY 1
Discontinued due to:
Placebo Group
(n=84)
Apremilast 30mg BID
(N=83)

Adverse
event
2

Lack of
efficacy
4

Withdrawn
consent
1

Other

Total

2

9

2

3

0

1

6

The third study by Strand et al., was a phase IIb, randomized, controlled study that
looked at improvements in patient reported outcomes with Apremilast therapy. The study had
four groups that were monitored through 16 weeks. Patients were randomly placed in groups
receiving one of the following; placebo, Apremilast 10mg BID, Apremilast 20mg BID,
Apremilast 30mg BID. All inclusion and exclusion criteria of the study can be found in Table 1.
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The mean change from baseline reported by the study showed overall a 4.4 point decrease in
DLQI scores in patients treated with Apremilast 30mg BID (Table 2). This particular study did
not give data concerning the number of patients who did not complete a full 16 weeks of therapy.
Last observation carried forward (LOCF) methodology was used to impute missing data.
DISCUSSION
The goal of this study was to determine if Apremilast 30mg could effectively lower
DLQI scores in patients in 16 weeks of therapy. With the analyzation of the three studies 30mg
Apremilast proved to decrease DLQI scores within the 16-week time frame.
Apremilast was approved by the FDA for treatment of patients with moderate to severe
plaque psoriasis who are candidates for phototherapy or systemic therapy as well as psoriatic
arthritis in March of 2014.13 Apremilast is also recognized by the brand name Otezla and is an
oral medication that can be taken without regards to food.14 Contraindications are not listed on
US labels but on Canadian labeling it is contraindicated in pregnancy and breast feeding.13
Common side effects listed include GI upset such as diarrhea, nausea, and vomiting.13
Neuropsychiatric effects include increased risk of depression and suicidal ideation.13 Weight loss
may also be a concerning side effect. Dosage reduction is also recommended in patients with a
CrCl <30 mL/min.13 With the listed contraindications and side effects a significant portion of
patients with psoriasis may not find Apremilast to be worth the shown treatment efficacy.
Especially concerning is that a patient already suffering from depression due to their skin
appearance may be put at an increased risk of harming themselves. It is important to monitor a
patient’s weight, renal function, and mood fluctuations regularly during therapy.
Cost and availability to patients is one of the largest draw backs. There is no generic
available to patients in the US and tablets cost approximately $65.66 per tablet.13 Coverage by
insurances varies and many require failed biologic therapy to get approval for the medication.15
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Currently Otezla offers a zero dollar copay for select patient populations and healthcare
providers may also fill out forms stating medical necessity to obtain coverage for their patients.14
There are multiple limitations noted throughout the studies. The use of LOCF assumes
that the missing data after patient's withdrawal are the same as the last value observed for that
patient. The consequence of this particular assumption is that it imputes data without giving
subject variability and it also alters the true sample size. All three studies used this methodology
when dealing with patients who discontinued therapy. Some studies allowed low-potency topical
corticosteroids as background therapy for face, axilla and groin psoriasis lesions, coal tar
shampoo and/or salicylic acid preparations for scalp lesions and non-medicated emollients for
body lesions were also permitted. Patients also were not prohibited from receiving live
vaccinations during some of the studies. There were also no protocol requirements to stop the
study medication for an infection in all studies. Infection side effects could cause DLQI scores to
fluctuate unrelated to study treatments. All of these listed factors could affect the validity of
results.
CONCLUSION
According to this EBM review Apremilast 30mg is effective in lowering DLQI scores in
patients with plaque psoriasis in 16 weeks of therapy. Some studies showed more significant
decreases in DLQI scores, but overall a patient would experience a lower impact of skin disease
on health-related quality of life. The three studies used tested large populations with patient
demographics being very closely matched within comparison groups. These factors helped to
increase the validity of the results.
For future research to improve from past studies, there should be consideration that social
interactions are at their peak during teenage years to young adulthood. The mean age studied was
approximately 45 years of age between the three studies. Additional studies should look to
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include a younger database of patients. Also, with first line treatment of plaque psoriasis being
topical therapies such as emollients, corticosteroids, and Vitamin D analogs, application would
typically be twice a day if using monotherapy. It would be important to compare compliance in
patients to see if an oral medication or topical medication, taken twice daily, is preferred by a
patient.
To face the large cost for the drug in today’s market it is important that future research is
aimed to directly compare other therapies such as biologics to Apremilast. This research should
aim to show that Apremilast is equally effective as well as safer for patient usage. Such future
research is warranted to help Apremilast gain more formulary coverage for patients with
commercial insurance.
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